Phenylketonurias Clinical Trial
Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels
Verified date | July 2014 |
Source | BioMarin Pharmaceutical |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective of this study is to evaluate the efficacy of Phenoptin™ (sapropterin dihydrochloride) in reducing blood phenylalanine (Phe) levels in subjects with phenylketonuria.
Status | Completed |
Enrollment | 89 |
Est. completion date | February 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 8 Years and older |
Eligibility |
Inclusion Criteria: - 8 years of age and older - Received at least 7 out of 8 scheduled doses in Study PKU 001 - Responsive to Phenoptin™ in Study PKU-001, defined as a reduction in blood Phenylalanine level of >/=30% compared with baseline - Blood Phenylalanine level >/=450 µmol/L at screening - Willing and able to provide written informed consent or, in the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained - Negative urine pregnancy test at screening (females of child-bearing potential) - Male and Female subjects of childbearing potential (if sexually active) must be using acceptable birth control measures, as determined by the investigator, and willing to continue to use acceptable birth control measures while participating in the study - Willing and able to comply with study procedures - Willing to continue current diet unchanged while participating in the study Exclusion Criteria: - Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable - Use of any investigational agent other than Phenoptin™ within 30 days prior to screening, or requirement for any investigational agent or investigational vaccine prior to completion of all scheduled study assessments - Pregnant or breastfeeding, or considering pregnancy - ALT >5 times the upper limit of normal (i.e., Grade 3 or higher based on World Health Organization Toxicity Criteria) at screening - Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes, or organ transplantation recipient) - Serious neuropsychiatric illness (e.g., major depression) not currently under medical management - Requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate) - Concurrent use of levodopa - Clinical diagnosis of primary BH4 deficiency |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
BioMarin Pharmaceutical |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Blood Phenylalanine Levels From Baseline to Week 6. | baseline to week 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05998109 -
PheCheck Feasibility Study
|
||
Not yet recruiting |
NCT04433728 -
Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
|
||
Completed |
NCT01209819 -
Bone Mineral Density in Adults With Hyperphenylalaninemia
|
N/A | |
Active, not recruiting |
NCT05174559 -
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
|
N/A | |
Not yet recruiting |
NCT04969809 -
Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients
|
N/A | |
Recruiting |
NCT04404530 -
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
|
||
Recruiting |
NCT05827536 -
Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.
|
N/A | |
Active, not recruiting |
NCT05971563 -
Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Completed |
NCT04368624 -
PKU Skin Stripping
|
||
Completed |
NCT04452513 -
A Prospective Clinical Study of Phenylketonuria (PKU)
|
||
Completed |
NCT05497050 -
The Effect of Nursing Empowerment Program
|
N/A | |
Completed |
NCT04943393 -
Remote Neurocognitive and Psychological Assessment in PKU
|
||
Completed |
NCT05096988 -
Evaluation of PKU Sphere Liquid
|
N/A | |
Completed |
NCT00225615 -
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
|
Phase 3 | |
Recruiting |
NCT05128149 -
Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
|
||
Terminated |
NCT05229549 -
Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria
|
N/A | |
Enrolling by invitation |
NCT05356377 -
Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
|
||
Not yet recruiting |
NCT06332807 -
AAV Gene Therapy Clinical Study in Adult Classic PKU
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06337864 -
Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria
|
N/A |